Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.12.2022 | original article

Corneal biomechanical assessment via ocular response analyzer following intravitreal aflibercept therapy

verfasst von: MD Betul Onal Gunay, Cenap Mahmut Esenulku

Erschienen in: Spektrum der Augenheilkunde

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

To assess changes in corneal biomechanical parameters measured by the Ocular Response Analyzer device (ORA, Reichert Inc., Depew, NY, USA) before and on the first day and the first week following intravitreal aflibercept (IVA) injection.

Methods

In this retrospective cross-sectional study, intraocular pressure (Goldmann applanation tonometry, IOPgat), ORA measurements (Goldmann-correlated intraocular pressure [IOPg], corneal-compensated IOP [IOPcc], corneal resistance factor [CRF], and corneal hysteresis) were made. Also, pachymetry and ocular biometric examination (anterior chamber depth, axial length, and lens thickness) were performed. Data before and on the first day and the first week after IVA injection were compared.

Results

In total, 51 patients (20 female [39.2%] and 31 male [60.8%]) were enrolled in the study. The mean age was 69.51 ± 8.43 years. Indication for IVA treatment was age-related macular degeneration in 22 patients (43.1%) and retinal vein occlusion in 29 patients (56.9%). No significant differences were observed following IVA in terms of central corneal thickness (p = 0.40), axial length (p = 0.80), anterior chamber depth (p = 0.69), and lens thickness (p = 0.49). IOPgat significantly reduced on the first day after IVA (13.3 mm Hg to 11.8 mm Hg; p < 0.001). A decrease in CRF was observed on the first day following IVA (9.94 to 9.38; p = 0.03). Furthermore, CRF and IOPgat were positively correlated at baseline and on the first day and the first week after IVA.

Conclusion

Intravitreal aflibercept treatment induces corneal biomechanical alterations that might be associated with IOP change following IVA injection.
Literatur
1.
Zurück zum Zitat Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013;27:787–94. CrossRefPubMed Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013;27:787–94. CrossRefPubMed
2.
Zurück zum Zitat Dedania VS, Bakri SJ. Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-related macular degeneration. Curr Opin Ophthalmol. 2016;27:224–43. CrossRefPubMed Dedania VS, Bakri SJ. Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-related macular degeneration. Curr Opin Ophthalmol. 2016;27:224–43. CrossRefPubMed
3.
Zurück zum Zitat Torres-Costa S, Ramos D, Brandão E, Carneiro Â, Rosas V, Rocha-Sousa A, et al. Incidence of endophthalmitis after intravitreal injection with and without topical antibiotic prophylaxis. Eur J Ophthalmol. 2021;31(2):600–6. CrossRefPubMed Torres-Costa S, Ramos D, Brandão E, Carneiro Â, Rosas V, Rocha-Sousa A, et al. Incidence of endophthalmitis after intravitreal injection with and without topical antibiotic prophylaxis. Eur J Ophthalmol. 2021;31(2):600–6. CrossRefPubMed
4.
Zurück zum Zitat Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011;56:95–113. CrossRefPubMed Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011;56:95–113. CrossRefPubMed
5.
Zurück zum Zitat Meyer CH, Michels S, Rodrigues EB, Hager A, Mennel S, Schmidt JC, et al. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol. 2011;89:70–5. CrossRefPubMed Meyer CH, Michels S, Rodrigues EB, Hager A, Mennel S, Schmidt JC, et al. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol. 2011;89:70–5. CrossRefPubMed
6.
Zurück zum Zitat Baek SU, Park IW, Suh W. Long-term intraocular pressure changes after intravitreal injection of bevacizumab. Cutan Ocul Toxicol. 2016;35:310–4. CrossRefPubMed Baek SU, Park IW, Suh W. Long-term intraocular pressure changes after intravitreal injection of bevacizumab. Cutan Ocul Toxicol. 2016;35:310–4. CrossRefPubMed
7.
Zurück zum Zitat Kling S, Hafezi F. Corneal biomechanics—a review. Ophthalmic Physiol Opt. 2017;37:240–52. CrossRefPubMed Kling S, Hafezi F. Corneal biomechanics—a review. Ophthalmic Physiol Opt. 2017;37:240–52. CrossRefPubMed
8.
9.
Zurück zum Zitat Shoeibi N, Ansari-Astaneh MR, Sedaghat MR, Shokoohi Rad S. Effect of intravitreal bevacizumab injection on corneal in vivo biomechanics: a pilot study. J Ophthalmic Vis Res. 2019;14:151–6. CrossRefPubMedPubMedCentral Shoeibi N, Ansari-Astaneh MR, Sedaghat MR, Shokoohi Rad S. Effect of intravitreal bevacizumab injection on corneal in vivo biomechanics: a pilot study. J Ophthalmic Vis Res. 2019;14:151–6. CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Bekmez S, Cakmak H, Kocaturk T, Cantas F, Dundar S. Biomechanical properties of the cornea following intravitreal ranibizumab injection. Graefes Arch Clin Exp Ophthalmol. 2021;259:691–6. CrossRefPubMed Bekmez S, Cakmak H, Kocaturk T, Cantas F, Dundar S. Biomechanical properties of the cornea following intravitreal ranibizumab injection. Graefes Arch Clin Exp Ophthalmol. 2021;259:691–6. CrossRefPubMed
11.
Zurück zum Zitat Goktas A, Goktas S, Atas M, Demircan S, Yurtsever Y. Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pressure. Cutan Ocul Toxicol. 2013;32:23–6. CrossRefPubMed Goktas A, Goktas S, Atas M, Demircan S, Yurtsever Y. Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pressure. Cutan Ocul Toxicol. 2013;32:23–6. CrossRefPubMed
12.
Zurück zum Zitat Kymionis GD, Giarmoukakis A, Apostolidi IK, Blazaki SV, Tsoulnaras KI, Moschandrea J, et al. Optical biometry derived axial length measurements following Intravitreal anti-vascular endothelial growth factor treatment for macular edema. Semin Ophthalmol. 2018;33:488–91. CrossRefPubMed Kymionis GD, Giarmoukakis A, Apostolidi IK, Blazaki SV, Tsoulnaras KI, Moschandrea J, et al. Optical biometry derived axial length measurements following Intravitreal anti-vascular endothelial growth factor treatment for macular edema. Semin Ophthalmol. 2018;33:488–91. CrossRefPubMed
13.
Zurück zum Zitat Bracha P, Moore NA, Ciulla TA, WuDunn D, Cantor LB. The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: a review. Surv Ophthalmol. 2018;63:281–95. CrossRefPubMed Bracha P, Moore NA, Ciulla TA, WuDunn D, Cantor LB. The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: a review. Surv Ophthalmol. 2018;63:281–95. CrossRefPubMed
14.
Zurück zum Zitat Cui QN, Gray IN, Yu Y, VanderBeek BL. Repeated intravitreal injections of antivascular endothelial growth factors and risk of intraocular pressure medication use. Graefes Arch Clin Exp Ophthalmol. 2019;257:1931–9. CrossRefPubMedPubMedCentral Cui QN, Gray IN, Yu Y, VanderBeek BL. Repeated intravitreal injections of antivascular endothelial growth factors and risk of intraocular pressure medication use. Graefes Arch Clin Exp Ophthalmol. 2019;257:1931–9. CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Atchison EA, Wood KM, Mattox CG, Barry CN, Lum F, MacCumber MW. The real-world effect of intravitreous anti-vascular endothelial growth factor drugs on intraocular pressure: an analysis using the IRIS registry. Ophthalmology. 2018;125:676–82. CrossRefPubMed Atchison EA, Wood KM, Mattox CG, Barry CN, Lum F, MacCumber MW. The real-world effect of intravitreous anti-vascular endothelial growth factor drugs on intraocular pressure: an analysis using the IRIS registry. Ophthalmology. 2018;125:676–82. CrossRefPubMed
16.
Zurück zum Zitat Kahook MY, Ammar DA. In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma. 2010;19:437–41. CrossRefPubMed Kahook MY, Ammar DA. In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma. 2010;19:437–41. CrossRefPubMed
17.
Zurück zum Zitat Ford KM, Saint-Geniez M, Walshe TE, D’Amore PA. Expression and role of VEGF—a in the ciliary body. Invest Ophthalmol Vis Sci. 2012;53:7520–7. CrossRefPubMedPubMedCentral Ford KM, Saint-Geniez M, Walshe TE, D’Amore PA. Expression and role of VEGF—a in the ciliary body. Invest Ophthalmol Vis Sci. 2012;53:7520–7. CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Hashemi H, Jafarzadehpur E, Mehravaran S, Yekta A, Ostadimoghaddam H, Norouzirad R, et al. Corneal resistance factor and corneal hysteresis in a 6- to 18-year-old population. J Cataract Refract Surg. 2014;40:1446–53. CrossRefPubMed Hashemi H, Jafarzadehpur E, Mehravaran S, Yekta A, Ostadimoghaddam H, Norouzirad R, et al. Corneal resistance factor and corneal hysteresis in a 6- to 18-year-old population. J Cataract Refract Surg. 2014;40:1446–53. CrossRefPubMed
19.
Zurück zum Zitat Broman AT, Congdon NG, Bandeen-Roche K, Quigley HA. Influence of corneal structure, corneal responsiveness, and other ocular parameters on tonometric measurement of intraocular pressure. J Glaucoma. 2007;16:581–8. CrossRefPubMed Broman AT, Congdon NG, Bandeen-Roche K, Quigley HA. Influence of corneal structure, corneal responsiveness, and other ocular parameters on tonometric measurement of intraocular pressure. J Glaucoma. 2007;16:581–8. CrossRefPubMed
20.
Zurück zum Zitat Dackowski EK, Moon JY, Wang J, Shrivastava A, Schultz JS. The relationship between corneal biomechanics and Intraocular pressure dynamics in patients undergoing intravitreal injection. J Glaucoma. 2021;30:451–8. CrossRefPubMed Dackowski EK, Moon JY, Wang J, Shrivastava A, Schultz JS. The relationship between corneal biomechanics and Intraocular pressure dynamics in patients undergoing intravitreal injection. J Glaucoma. 2021;30:451–8. CrossRefPubMed
21.
Zurück zum Zitat Caruso A, Füth M, Alvarez-Sánchez R, Belli S, Diack C, Maass KF, et al. Ocular half-life of intravitreal biologics in humans and other species: meta-analysis and model-based prediction. Mol Pharm. 2020;17:695–709. PubMed Caruso A, Füth M, Alvarez-Sánchez R, Belli S, Diack C, Maass KF, et al. Ocular half-life of intravitreal biologics in humans and other species: meta-analysis and model-based prediction. Mol Pharm. 2020;17:695–709. PubMed
22.
Zurück zum Zitat Foster PJ, Broadway DC, Garway-Heath DF, Yip JL, Luben R, Hayat S, et al. Intraocular pressure and corneal biomechanics in an adult British population: the EPIC-Norfolk eye study. Invest Ophthalmol Vis Sci. 2011;52:8179–85. CrossRefPubMed Foster PJ, Broadway DC, Garway-Heath DF, Yip JL, Luben R, Hayat S, et al. Intraocular pressure and corneal biomechanics in an adult British population: the EPIC-Norfolk eye study. Invest Ophthalmol Vis Sci. 2011;52:8179–85. CrossRefPubMed
23.
Zurück zum Zitat Terai N, Raiskup F, Haustein M, Pillunat LE, Spoerl E. Identification of biomechanical properties of the cornea: the ocular response analyzer. Curr Eye Res. 2012;37:553–62. CrossRefPubMed Terai N, Raiskup F, Haustein M, Pillunat LE, Spoerl E. Identification of biomechanical properties of the cornea: the ocular response analyzer. Curr Eye Res. 2012;37:553–62. CrossRefPubMed
Metadaten
Titel
Corneal biomechanical assessment via ocular response analyzer following intravitreal aflibercept therapy
verfasst von
MD Betul Onal Gunay
Cenap Mahmut Esenulku
Publikationsdatum
01.12.2022
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-022-00534-9